Pharmacokinetics of doxorubicin in sarcoma patients
- 1 January 1987
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 31 (6) , 695-699
- https://doi.org/10.1007/bf00541297
Abstract
The pharmacokinetics of doxorubicin has been studied in 26 sarcoma patients receiving polychemotherapy. Mean elimination half-life was 34.7±16.6 h and the total plasma clearance was 29.5±9.31·h−1·m−2. No relationship was found between the pharmacokinetic parameters and the response to treatment, or its toxicity. Special attention was paid to the early-phase kinetics of the drug (3–20 min after injection). A correlation between the early clearance and the ages of the patients was observed. The early clearance was clearly correlated with the total plasma clearance measured over 48 h after injection, indicating the importance of the distribution phase in the overall kinetics of the drug.Keywords
This publication has 9 references indexed in Scilit:
- Cellular Pharmacology of Doxorubicin in Sensitive and Resistant Rat Glioblastoma Cells in CultureOncology, 1986
- Tentative dose-monitoring of doxorubicin in lymphoma patientsMedical Oncology and Tumor Pharmacotherapy, 1985
- Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading systemInternational Journal of Cancer, 1984
- Early-phase pharmacokinetics of doxorubicin in non-hodgkin lymphoma patientsCancer Chemotherapy and Pharmacology, 1983
- Pharmacokinetics of adriamycin in patients with breast cancer: Correlation between pharmacokinetic parameters and clinical short-term responseEuropean Journal of Cancer and Clinical Oncology, 1982
- Extraction of Anthracyclines from Biological Fluids for HPLC EvaluationJournal of Liquid Chromatography, 1980
- Liquid Chromatographic Analysis of Adriamycin and Metabolites in Biological FluidsJournal of Liquid Chromatography, 1978
- Dose response evaluation of adriamycin in human neoplasiaCancer, 1977